AAAAAA

   
Results: 1-10 |
Results: 10
Low-molecular-weight heparin administration in patients with end-stage renal disease - Author's reply
Authors: Brophy, DF Wazny, LD Gehr, TWB Comstock, TJ Venitz, J
Citation: Df. Brophy et al., Low-molecular-weight heparin administration in patients with end-stage renal disease - Author's reply, PHARMACOTHE, 21(8), 2001, pp. 1017-1019
The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease
Authors: Brophy, DF Wazny, LD Gehr, TWB Comstock, TJ Venitz, J
Citation: Df. Brophy et al., The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease, PHARMACOTHE, 21(2), 2001, pp. 169-174
Pharmacokinetics and blood pressure response of losartan in end-stage renal disease
Authors: Sica, DA Halstenson, CE Gehr, TWB Keane, WF
Citation: Da. Sica et al., Pharmacokinetics and blood pressure response of losartan in end-stage renal disease, CLIN PHARMA, 38(6), 2000, pp. 519-526
Chronically increased intra-abdominal pressure produces systemic hypertension in dogs
Authors: Bloomfield, GL Sugerman, HJ Blocher, CR Gehr, TWB Sica, DA
Citation: Gl. Bloomfield et al., Chronically increased intra-abdominal pressure produces systemic hypertension in dogs, INT J OBES, 24(7), 2000, pp. 819-824
Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatinto reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia
Authors: Brophy, DF Wallace, JF Kennedy, DT Gehr, TWB Holdford, DA
Citation: Df. Brophy et al., Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatinto reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia, PHARMACOTHE, 20(8), 2000, pp. 952-959
Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease
Authors: Sica, DA Gehr, TWB Fernandez, A
Citation: Da. Sica et al., Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease, DRUG SAFETY, 22(5), 2000, pp. 350-360
The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis
Authors: Pedro, AA Gehr, TWB Brophy, DF Sica, DA
Citation: Aa. Pedro et al., The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis, J CLIN PHAR, 40(4), 2000, pp. 389-395
Disposition and safety of omapatrilat in subjects with renal impairment
Authors: Sica, DA Liao, WC Gehr, TWB Khan, S Jemal, M Delaney, CL Ferreira, IM Malhotra, BK
Citation: Da. Sica et al., Disposition and safety of omapatrilat in subjects with renal impairment, CLIN PHARM, 68(3), 2000, pp. 261-269
Effect of increased renal venous pressure on renal function
Authors: Doty, JM Saggi, BH Sugerman, HJ Blocher, CR Pin, R Fakhry, I Gehr, TWB Sica, DA
Citation: Jm. Doty et al., Effect of increased renal venous pressure on renal function, J TRAUMA, 47(6), 1999, pp. 1000-1003
The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency
Authors: Gehr, TWB Tenero, DM Boyle, DA Qian, Y Sica, DA Shusterman, NH
Citation: Twb. Gehr et al., The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency, EUR J CL PH, 55(4), 1999, pp. 269-277
Risultati: 1-10 |